Aphaia Pharma is a Zug, Switzerland, headquartered clinical-stage biopharmaceutical firm.

It harnesses proprietary precision-targeted drug supply expertise to revive endogenous hormone launch within the gastrointestinal tract to deal with and stop metabolic issues comparable to weight problems and related ailments. 

Aphaia’s lead candidate, APH-012, a glucose formulation, has been proven to securely restore endogenous hormone launch in people with weight problems. APH-012 is now being evaluated in a part 2 trial within the U.S. and Germany for continual weight administration and is getting ready to be evaluated in a second part 2 trial for the development of pre-diabetes in people with a pathological oral glucose tolerance check (OGTT).

The design of Aphaia’s expertise platform gives a possibility for the event of remedies for a number of illness patterns.

At Bio-Europe, we had a dialog about Aphaia with Steffen-Sebastian Bolz, the corporate’s chief scientific officer.

Source link